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Genetic approaches in the clinical investigation of complex dis- the mortality rate remains extremely high. Although
orders: Malnutrition, inflammation, and atherosclerosis (MIA) ESRD patients demonstrate a high prevalence of both
as a prototype. Despite major research efforts and improve- traditional (i.e., diabetes, hypertension, smoking) andments in dialysis technology, patients with end-stage renal dis-
nontraditional (i.e., malnutrition, inflammation, and ath-ease (ESRD) experience an extremely high mortality, which
erosclerosis—the MIA syndrome) risk factors for cardio-seems to be increasingly related to cardiovascular disease. Car-
diovascular disease has been linked to the presence of systemic vascular disease (the leading cause of morbidity and mor-
inflammation and malnutrition (MIA syndrome), in addition tality in this population), the mechanisms underlying the
to the high prevalence of traditional risk factors observed in development of complications of renal disease and theESRD patients. Since the mechanisms underlying the develop-
individual or collective contributions of risk factors arement of these complications of ESRD are largely unknown,
still largely unknown. Therefore, new strategies for iden-new strategies for identification of risk factors, pathophysio-
logic pathways, and targets for intervention are warranted. tification of risk factors, pathophysiologic pathways, and
Although the combined impact of MIA complications seems targets for intervention are warranted. Family- and pop-
to determine the extremely poor clinical outcome in the ESRD
ulation-based epidemiology, as well as the cloning ofpatients, there are significant unexplained individual differ-
several genes responsible for familial aggregation of re-ences in the development of the MIA syndrome, implying that
genetic differences might play a role. The vast information nal disease, suggests that renal disease initiation, pro-
generated by the advances in molecular genetics offers a great gression, and development of complications are at least
opportunity to analyze the causes of differences not only in in part genetically determined [1]. Moreover, althoughour susceptibility to (or protection from) various diseases, but
the combined impact of MIA complications seems toalso in the age of onset, severity of illness, and in the way our
determine the extremely poor clinical outcome in thebodies respond to treatment. In this review, we summarize an
integrated approach in the investigation of complex disorders, ESRD patients [2], there are significant unexplained in-
requiring the interactive collaboration between laboratory, dividual differences in the development of the MIA syn-
clinical, and epidemiologic resources using the MIA syndrome
drome, implying that genetic differences might play a role.as a prototype. We focus on the application of common genetic
With the landmark publication of the human genomevariations (single nucleotide polymorphisms [SNPs]) in associa-
tion with studies to generate potential risk profiling using data sequence [3, 4], genetic approaches are becoming in-
from multiple vulnerability genes. The appropriate application creasingly popular in understanding and characterizing
of this approach may be essential in the early identification of the variation in the human genome and its impact on ahigh-risk individuals and groups of patients for whom specific
disease or trait. A large database of variants has beentherapeutic interventions are indicated, thus creating a tailor-
subsequently reported [5], offering a unique opportunitymade clinical management for the future.
to analyze the causes of differences not only in our sus-
ceptibility to (or protection from) various diseases, but
End-stage renal disease (ESRD) is a serious health also in the age of onset, severity of illness, and in the
problem worldwide, and despite a major emphasis on way our bodies respond to treatment.
research and technology improvement in dialysis care, A number of strategies are available today for identi-
fying candidate genes or polymorphisms associated with
disease phenotypes. For Mendelian diseases with highKey words: malnutrition, atherosclerosis, single neucleotide polymor-
phisms, ESRD, inflammation. penetrance due to mutations in a single gene, such as
polycystic kidney disease, linkage studies have been very 2003 by the International Society of Nephrology
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successful in mapping the disease loci because of the types is run by the Karolinska Institutet: (htpp://hgbase.
cgr.ki.se).availability of families with multiple affected members.
In the 1980s, SNPs were detected using restrictionIn contrast to monogenic conditions, complex diseases
enzymes to identify the presence or absence of cuttingsuch as ESRD and complex traits, such as complications
sites and scored by observing the resulting fragmentduring the course of ESRD and during renal replacement
length variation. In the 1990s, SNPs were largely replacedtherapy, could have a number of determinants, including
by microsatellites, or simple tandem repeats (STR), as thepredisposing comorbidities (i.e., diabetes mellitus, hy-
marker of choice for linkage studies. STR shows highpertension, glomerulopathies), dialysis related factors,
levels of allelic variation, is widely and evenly distributedand genetic variation. Indeed, complications of ESRD,
across the human genome, and can be genotyped usingsuch as cardiovascular disease, malnutrition, and sys-
polymerase chain reaction (PCR) amplification. How-temic inflammation may be the result of combined effects
ever, SNPs became popular as genetic markers again inof variation at multiple interacting genes, each one mod-
the late 1990s, particularly due to a change in the typeestly contributing to a disease or trait. Unfortunately,
of genetic studies being performed. SNPs appear to belinkage analysis has limited power to detect such small
a much more useful tool in polygenic disorders such ascontributions of individual genes to a phenotype, and
ESRD, diabetes mellitus, cardiovascular and inflamma-attempts to identify genes involved in complex disease
tory diseases, which occur at a much higher frequencyusing linkage-based approaches have proved to be gener-
than single gene disorders. SNPs are highly abundant andally disappointing. In theory, association studies with a
are perceived as being more stable than STRs due tolarge sample size (but still much lower than for linkage
lower mutation rates. Like STRs, SNPs can be used asstudies), in which cases of disease or trait are compared
surrogate markers, but many SNPs may also have func-with a matched control from the same population are
tional consequences if they occur in the coding or regula-likely to have a greater chance of detecting small effects
tory regions of a gene. Therefore, by using SNP markers,of individual genes on the phenotype.
it is often possible to directly test for association between
a phenotype and a functional variant. For these reasons,
SNPs have been chosen as the basis for the high-densityGENETIC VARIATIONS USED IN LINKAGE
genetic marker maps required for the next phase of hu-AND ASSOCIATION STUDIES
man genetics: the unraveling of complex genetic traits.A number of different types of genetic variants (the
SNP-based association studies can be performed inexistence of two or more alleles at significant frequencies
two ways: direct testing of an SNP with functional conse-in a population) are found in the human genome, for
quence for association with a disease trait; or using a setexample, insertion/deletions, mini- and microsatellites
of SNPs as a marker for linkage disequilibrium (LD).(di, tri-, and tetranucleotide repeats), and single nucleo-
LD is generally defined as the presence of linked poly-tide polymorphisms (SNPs). By far, the most common
morphisms in the same region, thereby defining haplo-variants in the human genome sequence (more than 90%
types that can be used to identify regions of the genomeof the total) are SNPs. The genomic DNA sequence
associated with disease in a population. This strategyis a linear combination of four nucleotides, and if one
reduces the total number of variations, and has provedcompares two allelic sequences position by position, dif-
to increase the strength of SNP analysis, since in thisferent nucleotides at the same position represent a SNP.
case “the whole is greater than the sum of the parts.”
The 1.42 million known SNPs are found at a density
of one SNP per 1.91 kilobases. Beyond the numbers, the
NEW METHODS FOR SNP ANALYSISexcitement today comes from precise public knowledge
of where these sites of variation are in the genome, due The new strategies for association studies require the
to a collaborative effort of a group of pharmaceutical development of high-throughput SNP genotyping systems.
companies and information processing companies: (htpp:// Recently, a new straightforward sequencing method,
snp.cshl.org/db/snp/map). The International SNP Map Pyrosequencing was introduced (Pyrosequencing AB,
Working Group [5] estimates that they have identified Uppsala, Sweden). This method is based on sequencing
60,000 SNPs within genes (coding SNPs), or one coding by synthesis and on real-time pyrophosphate detection,
SNP per 1.08 kilobases of gene sequence. Moreover, 93% which, in several aspects, may be advantageous com-
of genes contain a SNP, and at present, nearly every pared to already existing methodologies [6]. The techni-
human gene and genomic region is marked by a known cal platform employed involves a highly automated se-
sequence variation. A comprehensive summary of all quencing instrument, allowing analysis of 96 samples in
known sequence variations in the human genome, orga- 10 to 15 minutes. The method relies on the fact that
nized to facilitate research on how genotypes affect com- pyrophosphate (PPi) is released as a result of nucleotide
incorporation during DNA synthesis, and, most impor-mon diseases, drug responses, and other complex pheno-
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Fig. 1. Representation of the genetic ap-
proaches in the investigation of complex disor-
ders, which requires an interactive collaboration
between laboratory, clinical, and epidemiologic
resources.
tantly, for every incorporation event, the release is equi- tigation. For such a complex phenotype, we may easily
assume that hundreds of different factors may be in-molar to the number of nucleotides incorporated. PPi
quantification is performed by indirect luminometric de- volved in its development. The choice of appropriate
susceptibility genes therefore requires thorough field-tection using a CCD camera, permitting parallel, real-
work. Some of the data produced by us and others usingtime analysis of all samples. The pyrosequencing process
association studies of gene variants and phenotypes re-has been fully automated and adapted to screenings of
lated to malnutrition, inflammation, and atherosclerosislarge SNP panels. The simplicity of the method allows
will be discussed in the following section.SNP genotyping to become accessible for personnel
other than specialized researchers, which, from our expe-
Malnutritionrience, makes it suitable for clinical genetic testing of
Protein-energy malnutrition with muscle wasting islarge patient materials.
present in a large proportion of ESRD patients and is
a strong risk factor for mortality in this patient group
CANDIDATE GENES FOR THE [8]. A number of factors may account for the high preva-
INVESTIGATION OF COMPLICATIONS lence of malnutrition in these patients. Recently, various
OF ESRD satiety-regulating hormones have attracted interest
Once the methodologic approach is defined for a par- among nephrologists. One such example is serum leptin,
ticular disease study (in this case the use of association a fat-produced hormone that is inappropriately elevated
studies in ESRD), the next step is to delineate candidate in most, but not all, ESRD patients and has been sug-
genes for investigation. In contrast to linkage studies, gested to be one of the factors contributing to anorexia
association studies require previous understanding of and weight loss in ESRD patients [9]. Although a silent
pathophysiologic pathways involved in a particular trait. mutation at codon 25 (CAA/CAG, glutamine) may be
Therefore, functional in vitro and in vivo experiments linked to morbid obesity in a Japanese nonuremic popu-
should be used as a background to determine whether lation [10], no studies, to the best of our knowledge,
a particular genetic variant is involved in the develop- have yet been conducted to study the impact of leptin
ment of a phenotype. Using the malnutrition, inflamma- polymorphisms in ESRD patients. Another peptide pro-
tion, and atherosclerosis (MIA) syndrome as a prototype duced by fat tissue is adiponectin, which is a protein
[7], we have developed an approach (Fig. 1) based on with anti-inflammatory effects on the components of the
the concept that several genes encoding proteins, which vascular wall that accumulates as renal function deterio-
are pathophysiologically related to observed patient phe- rates. Recently, Zoccali et al [11] observed that high
plasma adiponectin levels were associated with betternotypes, are candidates for MIA syndrome genetic inves-
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survival in ESRD patients, which is of interest since two kine that has been shown to block atherosclerotic events
in vitro [22]. Interestingly, there is large interindividualSNPs have been identified in the positions 45 and 276
in the adiponectin gene (APM1). The presence of the variation in IL-10 response to inflammation, at least 70%
of which may be explained by genetic factors [23]. In-G allele in the 276 position has been associated with
lower plasma adiponectin levels in type 2 diabetic pa- deed, the SNPs identified in the promoter region of the
IL-10 gene are related to IL-10 expression, and the risktients [12]. In a preliminary study, we confirmed this
finding and also demonstrated a higher prevalence of of both SLE [24] and inflammatory bowel disease [25].
Moreover, Girndt et al [26] have recently shown thatCVD in ESRD patients with the G/G genotype in the
position 45 in comparison to the T/G and T/T genotypes the IL-10 1082 SNP was associated with an increased
risk of cardiovascular events in hemodialysis patients. In(abstract; Pecoits-Filho et al, J Am Soc Nephrol 13:519A,
2002). contrast, another recent study analyzed both TNF-
and IL-10-common SNPs in a large cohort of nonrenal
Inflammation patients submitted to angiography and found no associa-
tions compared to matched controls between six differ-Inflammation, which is a common feature in ESRD,
has recently been shown to be an independent risk factor ent and functionally relevant polymorphisms of these
genes with the risk of atherosclerotic CVD [27].for cardiovascular disease in dialysis patients [13]. The
causes of the high prevalence of elevated C-reactive pro- Another polymorphism that might contribute to dif-
ferent inflammatory responses is the C825T polymor-tein (CRP) levels remain unknown, although it seems
conceivable that both dialysis-related (such as dialysis phism in the GNB3 gene, encoding the ubiquitously ex-
pressed b3-subunit of the G proteins, which is involvedmembrane and water quality) and non–dialysis-related
factors (such as residual renal function, co-morbidity, in immune cell function in humans. In a preliminary
prospective study including 228 HD patients, higher CRPand genetic factors) might contribute. In nonrenal pa-
tients, a 1059G/C SNP within exon 2 of the CRP gene levels and higher mortality was seen in T homozygotes,
suggesting that the C825T polymorphism might influencehas been described, and may be of importance since
plasma CRP concentrations were reduced among carriers mortality rate in HD patients (abstract; Zimmermann
et al, J Am Soc Nephrol 10:A1369, 1999). Soluble cellularof the C allele as compared with noncarriers [14]. How-
ever, in another study, this genotype variant was not asso- adhesion molecules (ICAM-1, VCAM-1, and E-selectin)
are a group of molecules that are expressed on the sur-ciated with increased risk of arterial thrombosis [15].
Serum levels of CRP appear to reflect the generation face of vascular endothelial cells in response to pro-
inflammatory cytokines, and may play a central role inof pro-inflammatory cytokines such as interleukin-1
(IL-1), interleukin-6 (IL-6), and tumor necrosis factor- the early atherosclerotic events. We have found mark-
edly elevated levels of cellular adhesion molecules inalpha (TNF-), all of which are markedly up-regulated
in ESRD [16]. Since circulating cytokine levels vary con- ESRD patients who are inflamed, malnourished, and
have signs of CVD [28]. As at least two polymorphismssiderably among ESRD patients, one may speculate that
genetic factors, such as polymorphisms in genes encoding that could influence the mechanisms of ICAM-1 action
(R241 in exon 4, and E469 in exon 6 of the ICAM-1pro-inflammatory cytokines, may be involved in de-
termining the individual inflammatory reaction in re- gene) have been documented [29], further studies are
needed to examine the impact of these SNPs on compli-sponse to a given insult. In this respect, a number of
different cytokine polymorphisms might be of interest. cations and survival in ESRD patients.
For example, among nonrenal patients with myocardial
Atherosclerosisinfarction, an increased IL-1 allele 2 frequency was ob-
served in those of younger age and with higher CRP Cardiovascular complications caused by an acceler-
ated atherosclerotic disease are the principal causes oflevels [17]. Moreover, Berger et al [18] recently reported
that IL-1 gene polymorphisms are highly related to both morbidity and mortality in ESRD patients. Although it
is documented that both traditional and nontraditionalplasma levels of CRP and fibrinogen in patients referred
for angiography. IL-6 is another pro-inflammatory cyto- risk factors contribute to the excessive risk of CVD,
genetic factors are also likely to contribute, and severalkine that is strongly associated with the presence of mal-
nutrition, inflammation, and atherosclerosis [19], and different SNPs may be of clinical importance. For exam-
ple, in both the general population and among ESRDmortality [20] in ESRD patients. Several SNPs have been
identified within the IL-6 promoter region. The most patients, cross-sectional studies have shown that the epsi-
lon 4 allele of the apolipoprotein E (ApoE) gene iswell studied variation in the promoter region of the IL-6
gene is the 174G/C SNP, and the C/C genotype has associated with an increased risk of atherosclerotic CVD
[30]. In addition, it has been reported that ApoE maybeen related to higher levels of plasma IL-6, particularly
after stresses such as surgical procedures [21]. play an important role in lipoprotein metabolism, and
variations at the ApoE locus has been reported to affectIL-10 is a clinically important anti-inflammatory cyto-
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LDL cholesterol levels in CAPD subjects, suggesting lation of experimental studies on interesting pathophysi-
ologic pathways or broad gene expression-profiling experi-that epsilon 4-carriers may be more susceptible to accel-
ments. Once candidate genes are identified and sequenced,erated development of atherosclerosis in this condition
their frequency in healthy and diseased populations, such[31]. However, a recent study including 269 hemodialysis
as ESRD and pre-ESRD patients, can be compared. Aspatients indicated that, although ApoE polymorphisms
has been suggested by previous studies, it is highly un-significantly affected serum levels of total cholesterol
likely that an individual SNP will be singled out as theand LDL-cholesterol, it was not associated with the pres-
sole predictor of risk factors such as the MIA syndrome.ence of atherosclerosis [32]. Thus, the association be-
Instead, we believe that a combination of relevant SNPstween ApoE polymorphisms and atherosclerosis still re-
will ultimately prove to be invaluable for the identifica-mains unclear in ESRD patients. Homocysteine, an
tion of independent or codependent predictors of theseamino acid that accumulates in renal failure and may
complications and also factors determining the progres-accelerate atherosclerosis by enhancing lipoprotein oxi-
sion of renal disease to ESRD.dation and endothelial dysfunction, has been considered
The novel information generated by these associationby some investigators [33], but not all [34], to be a signifi-
studies has the potential to greatly improve treatmentcant risk factor for CVD in ESRD patients. Although
strategies for the renal disease population. This will allowthe C677T and A1298C polymorphisms in the methyl-
for: (1) the early identification of high-risk groups thatenetetrahydrofolate reductase (MTHFR) gene have
should be followed closely with more aggressive control/been shown to be associated with homocysteine plasma
treatment of related risk factors; (2) the recognition oflevels and CVD in dialysis patients [35], more studies
patients that will benefit the most from a specific treat-are needed to investigate if this polymorphism is associ-
ment such as pharmacologic intervention or, in the caseated with accelerated atherosclerosis in ESRD patients.
of ESRD, a particular dialytic modality; (3) the designAnother cause of accelerated atherosclerosis in ESRD
of more efficient clinical trials based on the selection ofpatients may be persistent infections, such as Chlamydia
patients according to specific genotypes (pharmacogeno-pneumoniae [36] and Helicobacter pylori. It is, therefore,
mics); and (4) the confirmation of in vivo relevance andof interest that Kiechl et al [37] recently described an as-
significance of pathophysiologic events described in ex-sociation between the Asp299Gly TLR4 polymorphism
perimental models, or identification of previously un-(diminishing the inflammatory response to gram-nega-
known pathologic pathways (basic research tool).tive pathogens) and a decreased risk of atherosclerosis
In summary, a new era of human genetic analysisin nonrenal patients. Myeloperoxidase (MPO), another
could have a major impact on the investigation of com-component of the defense system, is a hemoprotein ex-
plex disorders such as ESRD and its complications. Thepressed in polymorphonuclear leukocytes and mono-
scientific and technologic resources to systematically pur-cytes that catalyzes the production of hypochlorous acid,
sue the identification of gene variation that causes in-enhancing the antimicrobial activity. MPO has recently
heritable susceptibility to human disease and traits usingbeen linked to several diseases, such as atherosclerosis
genome-wide SNP association studies are evolving rap-and Alzheimer’s disease [38]. A highly functional SNP
idly. These resources include the public availability of athat affects the transcription of MPO is located in the
large number of SNP markers, the development of fast,promoter region (463G/A) [39], and may be of interest
inexpensive, and easy to perform genotyping techniques,
due to a recent description of an association between and a large number of well-characterized large popula-
this SNP and the presence of coronary artery disease tion databases. The utilization of these new tools for re-
[40]. Similarly, we have recently found that the463 G/A search into the diagnosis and therapy of human disease
SNP is associated with lower prevalence of CVD in a will require increased collaboration between clinical in-
group of 155 ESRD patients [41]. As this SNP was associ- vestigators, clinical and molecular geneticists, and bio-
ated with elevated serum levels of a surrogate marker informatics. The appropriate application of this approach
of advanced glycation end products (pentosidine), it may be essential in the early identification of high-risk
could be speculated that the observed differences in individuals and groups of patients for whom specific ther-
CVD prevalence are mediated by increased oxidative apeutic interventions are indicated, thus creating a tailor-
stress due to increased production of free radicals. made clinical management for the future.
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